The Latest Cardiac and Vascular News
IRVINE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) — MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic tests that addresses unmet clinical needs, announced today corrections to the second paragraph of its press release under the same headline sent out on August 8, 2025. The corrected release follows:
Physicians across the southern states can now implement SmartVascular Dx into their clinical offerings to help reduce the prevalence of vascular disease.
MorningStar Laboratories is now officially included in the Medicare fee schedule, enabling us to offer national medical coverage.
